Exercise plus supplement may rebuild muscle in young transplant survivors
NCT ID NCT05194397
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests whether a tailored exercise program combined with a dietary supplement called nicotinamide riboside (NR) can improve muscle mass, strength, and fitness in adolescents and young adults who had a bone marrow transplant for leukemia or other blood disorders. About 80 participants, aged 10 to 30, will be randomly assigned to receive NR or a placebo, and some will also do intensive exercise. The goal is to see if these interventions can reverse the muscle loss and reduced fitness that often follow transplant.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Nicotinamide Riboside (a vitamin B3-like dietary supplement)
- What this could lead to
- If it works, this could point toward a way to help young cancer survivors regain lost muscle strength and fitness after a bone marrow transplant.
- What could go wrong
- This is a small, early-phase trial (80 people) testing a supplement and exercise program. The supplement is not a proven treatment, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a drug revive blood cell production in children with aplastic anemia?